A breast cancer diagnosis often arrives as a profound turning point, bringing uncertainty and complex emotions. While the ...

Medically reviewed by Forest Miller, OTR/L When you are managing metastatic breast cancer, planning for the future is both ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...

Caring for someone with metastatic breast cancer can be demanding physically, emotionally, and financially, but there are ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...